A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 (EirGenix Trastuzumab) with Herceptin® as Neoadjuvant Treatment in Combination with Anthracycline/Paclitaxel-based Systemic Therapy in Patients with HER2-positive Early Breast Cancer. (November 2022) - Henneberg, J.; Grohmann-Izay, B.; Huang, C.S.; Schulze, C.; Llinas, N.; Giorgi, D.; Misra, A.; Pominchuk, D.; Prokhorof, A.; Rapoport, B.; Semiglazov, V.; Tseng, L.M.; et al.